Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO round-up: Mainstay raises €18m; Union MedTech takes step closer to REX with £10m

This article was originally published in Clinica

Executive Summary

Irish orthopedic firm Mainstay Medical has raised €18m ($25m) in its initial public offering, slightly less than its €23m target. According to The Irish Times, the firm sold around 850,000 shares at €21.15 each, at the low end of the €20-27 range it had previously given. The IPO was a dual listing on the Irish Stock Exchange and the Paris Euronext market. Mainstay will use the funds to conduct clinical trials of its ReActiv8 treatment for chronic low back pain, initially in Australia and then in Europe, and to submit an application for CE mark approval. ReActiv8 is an implanted device that stimulates nerves responsible for contracting the key muscles that stabilize the lower back. Medtech giant Medtronic is one of Mainstay’s investors.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel